secwatch / observer
RNGE RANGE IMPACT, INC.
CIK 0001438943 21 ready 8-Ks latest June 3, 2026, 4:05 PM ET RSS · JSON
Activity: NORMAL 2 filings / 30d vs 1 baseline
Ready 8-Ks 21
Latest filing June 3, 2026, 4:05 PM ET
Top materiality 0.85
Event mix other_material ×10 · earnings ×7 · m_and_a ×3
Sentiment 9 pos · 3 neg · 9 neu
Latest earnings reported 2026-Q1
Executive change recent →

Recent 8-K filings for RNGE

Executive changes

Role change

Richard McKilligan

Chief Financial Officer of Graphium Biosciences, Inc.
RNGE · RANGE IMPACT, INC.
Effective
2024-04-25
Successor
Patricia Missal
Filed
April 26, 2024, 7:59 PM ET
Mr. McKilligan will remain as Chief Financial Officer of Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company (“Graphium”).
Appointed

Patricia Missal

Chief Financial Officer
RNGE · RANGE IMPACT, INC.
Effective
2024-04-25
Filed
April 26, 2024, 7:59 PM ET
On April 25, 2024, the Board of Directors of Range Impact, Inc. (the “Company”) elected Patricia Missal as Chief Financial Officer, replacing Richard McKilligan who had previously served as the Company’s Chief Financial Officer, Counsel and Secretary.
Role change

Dr. Brandon Zipp

Chief Science Officer of Graphium
RNGE · RANGE IMPACT, INC.
Effective
2024-04-25
Filed
April 26, 2024, 7:59 PM ET
Dr. Brandon Zipp, who had served as the Company’s Chief Science Officer, will, effective April 25, 2024, serve exclusively as the Chief Science Officer of Graphium.

Earnings & guidance

2026-Q1 EPS reported -$0.02 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

9 positive 3 negative 9 neutral

source · RNGE on sec.gov